The therapeutic landscape for NRs has expanded with the approval of drugs like PPARγ agonists (pioglitazone, rosiglitazone) for diabetes, FXR agonists (obeticholic acid) for liver diseases, and selective TR agonists (resmetirom) for Metabolic dysfunction-Associated Steatohepatitis (MASH). Here, NR1H4 is linked to diabetes mellitus.